<br>        Inclusion Criteria:<br><br>          1. Subjects must provide informed consent prior to performance of study-specific<br>             procedures or assessments, and must be willing to comply with treatment and follow-up.<br>             Procedures conducted as part of the subject's routine clinical management (e.g., blood<br>             count, imaging study) and obtained prior to signing of informed consent may be<br>             utilized for screening or baseline purposes provided these procedures are conducted as<br>             specified in the protocol<br><br>          2. Histologically or cytological confirmed uterine leiomyosarcoma or uterine<br>             carcinosarcoma including any subtypes<br><br>          3. Patients with a contraindication for doxorubicin OR patients must have received prior<br>             chemotherapies<br><br>          4. For patients with prior anthracycline therapy normal cardiac function with LVEF at<br>             least 50% must be assessed by quantitative echocardiogram or MUGA scan<br><br>          5. Prior Gemcitabine containing chemotherapy is permitted provided that at least 8 weeks<br>             have elapsed since the last dose of therapy<br><br>          6. ECOG performance status 0-1<br><br>          7. At least 18 years old<br><br>          8. Measurable disease according to RECIST v 1.1 criteria (in case of tumour debulking -<br>             staging CT-scan after surgery)<br><br>          9. Able to swallow and retain oral medication<br><br>         10. Adequate organ system function as defined in Table 1<br><br>        Table 1: Definitions for Adequate Organ Function System Laboratory Values Hematologic<br>        Absolute neutrophil count (ANC) > = 1.5 X 109/L Hemoglobin1 > = 9 g/dL (5.6 mmol/L)<br>        Platelets > = 100 X 109/L Prothrombin time (PT) or international normalized ratio (INR)4 <=<br>        1.2 X upper limit of normal (ULN) Partial thromboplastin time (PTT) <=1.2 X ULN Hepatic2<br>        Total bilirubin <= 1.5 X ULN AST and ALT <= 2.5 X ULN Renal Serum creatinine <= 1.5 mg/dL<br>        (133 µmol/L)<br><br>        Or, if greater than 1.5 mg/dL:<br><br>        Calculated creatinine clearance > = 50 mL/min<br><br>        Urine Protein to Creatinine Ratio (UPC)3 < 1<br><br>          1. Subjects may not have had a transfusion within 7 days prior to screening assessment.<br><br>          2. Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN are not permitted<br><br>          3. If UPC > = 1, then a 24-hour urine protein must be assessed. Subjects must have a<br>             24-hour urine protein value <1g to be eligible.<br><br>          4. Subjects receiving anticoagulant therapy are eligible if their INR is stable and<br>             within the recommended range for the desired level of anticoagulation<br><br>        11. Non-childbearing potential (i.e., physiologically incapable of becoming pregnant),<br>        including any female who has had:<br><br>          -  A hysterectomy<br><br>          -  A bilateral oophorectomy (ovariectomy)<br><br>          -  A bilateral tubal ligation<br><br>          -  Is post-menopausal Subjects not using hormone replacement therapy (HRT) must have<br>             experienced total cessation of menses for = 1 year and be greater than 45 years in<br>             age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value >40<br>             mIU/mL and an estradiol value < 40pg/mL (<140 pmol/L).<br><br>        Subjects using HRT must have experienced total cessation of menses for >= 1 year and be<br>        greater than 45 years of age OR have had documented evidence of menopause based on FSH and<br>        estradiol concentrations prior to initiation of HRT<br><br>        OR<br><br>        Negative serum pregnancy test of women of childbearing potential performed within 1 week<br>        prior to the first dose of study treatment, preferably as close to the first dose as<br>        possible, and agrees to use adequate contraception. Acceptable contraceptive methods, when<br>        used consistently and in accordance with the product label and the instructions of the<br>        physicians are as followed for 14 days before exposure to investigational product, through<br>        the dosing period and for at least 21 days after the last dose of investigational product:<br><br>          -  Complete abstinence from sexual intercourse<br><br>          -  Oral contraceptive, either combined or progestogen alone<br><br>          -  Injectable progestogen<br><br>          -  Implants of levonorgestrel<br><br>          -  Estrogenic vaginal ring<br><br>          -  Percutaneous contraceptive patches<br><br>          -  Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate<br>             of less than 1% per year<br><br>          -  Male partner sterilization (vasectomy with documentation of azoospermia) prior to the<br>             female subject's entry into the study, and this male is the sole partner for that<br>             subject<br><br>          -  Double barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps)<br>             with a vaginal spermicidal agent (foam/gel/film/cream/suppository) Female subjects who<br>             are lactating should discontinue nursing prior to the first dose of study drug and<br>             should refrain from nursing throughout the treatment period and for 14 days following<br>             the last dose of study drug.<br><br>        Exclusion Criteria:<br><br>          1. Prior malignancy<br><br>             • Note: Subjects who have had another malignancy and have been disease-free for 5<br>             years, or subjects with a history of completely resected non-melanomatous skin<br>             carcinoma or successfully treated in situ carcinoma are eligible.<br><br>          2. Patient has received prior treatment with any anti-angiogenic agent including<br>             bevacizumab and tyrosine kinase inhibitors<br><br>          3. Active malignancy or any malignancy in the last 5 years prior to first dose of study<br>             drug other than LMS and CS<br><br>          4. History or clinical evidence of central nervous system (CNS) or leptomeningeal<br>             metastases, except for individuals who have previously-treated CNS metastases, are<br>             asymptomatic, and have had no requirement for steroids or anti-seizure medication for<br>             6 months prior to first dose of study drug. Screening with CNS imaging studies<br>             (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if<br>             clinically indicated or if the subject has a history of CNS metastases<br><br>          5. Clinically significant gastrointestinal abnormalities that may increase the risk for<br>             gastrointestinal bleeding including, but not limited to:<br><br>               -  Active peptic ulcer disease<br><br>               -  Known intraluminal metastatic lesion/s with risk of bleeding<br><br>               -  Inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease), or other<br>                  gastrointestinal conditions with increased risk of perforation<br><br>               -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal<br>                  abscess within 28 days prior to beginning study treatment<br><br>               -  Grade 3/4 diarrhea<br><br>          6. Corrected QT interval (QTc) > 450 Milliseconds using Barzett's formula<br><br>          7. History of any one or more of the following cardiovascular conditions within the past<br>             6 months:<br><br>               -  Cardiac angioplasty or stenting<br><br>               -  Myocardial infarct